EGFR (L792H)

EGFR · Variant type: point · HGVS: p.L792H

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Canertinib	97.6%	2.4%	96.49
2	Neratinib	97.4%	2.6%	93.18
3	Mobocertinib	96.7%	3.3%	97.22
4	Erlotinib	92.8%	7.2%	99.75
5	Lazertinib	90.9%	9.1%	97.47
6	Zanubrutinib	86.5%	13.6%	98.24
7	Vandetanib	85.1%	14.9%	95.74
8	Pralsetinib	51.3%	48.7%	93.43
9	Pacritinib	39.0%	61.0%	88.64
10	Defactinib	25.7%	74.3%	92.68
11	Avapritinib	18.4%	81.6%	97.73
12	Pirtobrutinib	17.1%	82.9%	99.49
13	Pemigatinib	14.5%	85.5%	98.23
14	Tepotinib	12.9%	87.1%	99.75
15	Alpelisib	11.8%	88.2%	97.22
16	Mitapivat	10.3%	89.7%	100.00
17	Tenalisib	10.3%	89.7%	97.98
18	Tucatinib	9.4%	90.6%	99.75
19	Erdafitinib	9.0%	91.0%	95.71
20	Palbociclib	8.2%	91.8%	98.75
21	Abrocitinib	8.1%	91.9%	99.50
22	Quizartinib	7.6%	92.4%	99.50
23	Selpercatinib	6.0%	94.0%	96.72
24	Acalabrutinib	4.6%	95.4%	99.50
25	Sorafenib	3.2%	96.8%	96.72

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Canertinib	97.6%	98.4%	-0.8%
Neratinib	97.4%	100.0%	-2.6%
Mobocertinib	96.7%	100.0%	-3.3%
Erlotinib	92.8%	99.4%	-6.6%
Lazertinib	90.9%	100.0%	-9.1%
Zanubrutinib	86.5%	88.2%	-1.7%
Vandetanib	85.1%	99.3%	-14.2%
Pralsetinib	51.3%	99.1%	-47.8%
Pacritinib	39.0%	—	—
Defactinib	25.7%	94.6%	-68.9%
Avapritinib	18.4%	—	—
Pirtobrutinib	17.1%	—	—
Pemigatinib	14.5%	—	—
Tepotinib	12.9%	—	—
Alpelisib	11.8%	—	—
Mitapivat	10.3%	—	—
Tenalisib	10.3%	—	—
Tucatinib	9.4%	—	—
Erdafitinib	9.0%	—	—
Palbociclib	8.2%	—	—
Abrocitinib	8.1%	—	—
Quizartinib	7.6%	—	—
Selpercatinib	6.0%	—	—
Acalabrutinib	4.6%	—	—
Sorafenib	3.2%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.6ms